Trials / Completed
CompletedNCT02688075
An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada
Prospective, Observational, 12-month Assessment of Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada (CANadian CAnagliflozin REgistry: CanCARE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 538 (actual)
- Sponsor
- Janssen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate canagliflozin use in the treatment of type 2 diabetes mellitus (T2DM) and generate evidence of its effectiveness, safety and patient-reported outcome (PRO) in a usual clinical practice in Canada.
Detailed description
This is a prospective, non-interventional, nation-wide, multicenter (more than one study site) study to evaluate the treatment of T2DM with canagliflozin in a usual clinical practice in Canada. Approximately 535 participants will be enrolled into this study. The planned study duration for each participant will be 12 months \[plus or minus (+/-) 4 weeks\], including 4 study visits in accordance with the usual clinical practice: enrollment and visits at 3, 6 and 12 months (+/- 4 weeks). Participants will primarily be observed for effectiveness, safety and PRO over an observational period of 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Intervention | Participants who are receiving Canagliflozin +/- other AHA as per usual clinical practice will be observed for effectiveness, safety and PRO. |
Timeline
- Start date
- 2015-11-13
- Primary completion
- 2017-08-17
- Completion
- 2017-08-17
- First posted
- 2016-02-23
- Last updated
- 2017-10-30
Locations
23 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02688075. Inclusion in this directory is not an endorsement.